Evolution of patients with synchronic brain metastasis of non-small cell lung cancer [Evolución de pacientes con metástasis cerebral sincrónica de carcinoma de pulmón no células pequeñas]

Objective: to determine and compare median (MS) and overall (OS) survivals of a group of patients with NSCLC and synchronic brain metastasis treated with multimodal therapy (MM) -neurosurgery + radio-chemotherapy-bimodal therapy (BM) -radio-chemotherapy- or radiotherapy alone (RT) Patients and methods: pts. with simultaneous diagnosis of NSCLC and brain metastasis were included. They were evaluated with toraco-abdominal CT scan, bone scintigraphy and brain CT scan. The work-up of pts. eligible for neurosurgery included a brain MRL Those pts. with one brain metastasis and adequate local (candidates to surgery) tumors were treated with MM. Pts. with multiple brain metastasis or inadequate local tumors were treated with BM or RT. Neurosurgery was adequated to metastasis location. Radiotherapy consisted in holocraneal 5,040 cGys and there were used two chemotherapy schemes (cisplatin 75 mgs-sqm on day 1, vinorelbine 20 mgs-sqm on days 1 and 8 and etoposide 60 mgs-sqm on days 1,2 and 3 or carboplatin AUC 6 and paclitaxel 200 mgs-sqm on day 1). The association of radio-chemotherapy was developed concurrently with the first cycle. MS and 1 year OS with Kaplan Meier method were determined. Results: from 388 patients with NSCLC treated between 1990 and 1999, 31 were included in the present study. Histology: adeno: 14 pts., squamous: 13 pts. Undifferenciated: 2 pts., Large Cells: 1 pt. Median follow-up for the entire group was 9.8 months. 16/31 pts. had one brain metastasis. 6 were treated with MM and 10 with BM. For pts. with MM, median age was 52.16 (r: 39-54) and MS and OS were 11.66 months and 12% respectively. For pts. with BM, median age was 64.4 (r: 43-78) and MS and OS were 2.8 months and 0% respectively. 15/31 pts. had multiple brain metastasis. 12 pts. received BM and 3 RT. For the first group, median age was 53 (r: 32-71), OS and MS were 4 months and 0% respectively and for the second median age was 54 (r: 38-63), OS and MS were 2.33 months and 0% respectively. One Brain Multiple Brain metastasis metastasis Treatment MM BM BM XRT Median Age 52.16 64.4 53 54.3 MS 11.6m 2.8m 3.18m 2.33 m 1 year OS 12% 0% 0% 0% Conclusions: pts. with brain metastasis of NSCLC had worst MS and OS than those with other metastatic localizations. This rates seems better when it is possible adding surgery to treatment.Fil: Richardet, Eduardo Arnoldo. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Carranza, L. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Bella, S. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Richardet, M. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: García Cocco, V. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Melchior, A. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Uribe Echeverría, A. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; Argentin

Phase II trial with navelbine + cisplatin + etoposide in the treatment of inoperable non-small cell lung carcinoma

40 patients with advanced non-small cell lung cancer not previously treated were included in a study at phase II with vinorelbine 20 mg/Sq.m days 1 and 8, etoposide 60 mg/sq.m days 1-3 and cisplatin 75 mg/sq.m day 1 each 28 days for 6 cycles. There were 31 men and 9 women, being the average age of 54 years, with "performance Status" grade 0-2. All of them could be evaluated for toxicity and 31 for responsiveness. 10 patients were in stage IIIb and 21 at stage IV. 42% of objective responses were obtained and an overall survival of 9 months, which justifies further studies.Fil: Richardet, Eduardo Arnoldo. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Carranza, L. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Uribe, A. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Tolocka, H. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Cresta, Cecilia. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Uribe, E. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Uribe, M. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; Argentin

Uracil/tegafur plus oral calcium folinate in advanced breast cancer

Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. Orzel, which combines UFT with the oral biomodulator, calcium folinate, may provide even greater antitumor efficacy against breast cancer. Here, we describe the preliminary results of this phase H trial investigating the feasibility of 250 mg/m2/day of UFT plus 45 mg/day of oral calcium folinate administered to highly pretreated patients with advanced breast cancer. The results indicate a highly tolerable regimen and an overall response rate of 27.8% in a group of poor-prognosis patients. These findings warrant continued investigation.Fil: Richardet, Eduardo Arnoldo. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Pedraza, Cecilia. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Mickiewicz, Elizabeth. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Lerzo, Guillermo. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Bonamasa, Miguel. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Coppola, Federico. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Elli, Alicia. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Uranga, Graciela. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Jovtis, Silvia. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Bruno, Mario. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Ventriglia, Mónica. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Cuevas, María Andrea. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; Argentin